What Infynity Biomarkers does

Infynity Biomarkers is a privately held French R&D biotechnology company founded in 2009 by Dr. Maan Zrein and Dr. Samih Darwazah and headquartered in Lyon. The firm is focused exclusively on infectious diseases and immunity, with a stated mission to identify new biomarkers of clinical interest and develop innovative serological assays for disease diagnosis, prognosis, and drug/vaccine efficacy monitoring. The company operates as a SAS with a share capital of €80,000 and a headcount of 1–10 employees, reflecting a small specialist R&D structure.

The core offering is a proprietary Multiplex Technology platform built on 96-well microplates capable of detecting up to 50 different antigens or antibodies simultaneously under identical experimental conditions. This platform is complemented by proprietary epitope mapping prediction algorithms used to identify serological hotspots and design optimal B-cell epitopes. Commercial product lines include Research Use Only (RUO) multiplex ELISA kits (Multi-SARS-CoV-2, Multi-Cruzi, Multi-HTLV), critical raw materials (recombinant antigens and antibodies for HCV, HIV, HTLV, Chagas, Onchocerciasis, and Syphilis), recombinant antibody design services, and tailored customized development services. A new point-of-care platform called MAGESTICS is being co-developed with MAGIA Diagnostics and Grenoble Alpes Hospital.

Revenue is generated through one-time RUO kit sales, raw material product sales, and project-based professional services for IVD companies, academic research institutions, healthcare organizations, and global health bodies such as DNDi and FIND. Distribution is primarily direct B2B via website inquiries, supplemented by scientific publications in high-impact journals and partnership-driven global reach spanning 20+ countries. Pricing is not publicly disclosed and is quote-based. Strategic partnerships include an integration with Quotient Limited's MosaiQ blood screening platform and co-development projects underwritten by BPI France and Rhône Alpes Region.

Name

Infynity Biomarkers

Legal name

SAS Infynity Biomarkers

Website

https://infynity-biomarkers.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

Infynity Biomarkers is a French R&D biotech founded in 2009 in Lyon, specializing in multiplex immunoassay technology for infectious disease diagnostics. It sells RUO kits, critical raw materials, and custom services to IVD companies, academic researchers, and global health organizations.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)

akta.pro primary industry

Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)

akta.pro secondary industries

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB)

Keywords

• Multiplex immunoassays
• In vitro diagnostics
• Biomarker discovery
• Infectious disease serology
• Recombinant antigens

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Multiplex Immunoassay Kits (RUO): Sale of Research Use Only multiplex immunoassay kits including Multi-SARS-CoV-2, Multi-Cruzi, and Multi-HTLV kits for diagnostic development and research purposes.
2. Critical Raw Materials: Sale of recombinant antigens and antibodies for infectious disease agents including HCV, HIV, HTLV, Chagas, Onchocerciasis, and Syphilis for IVD assay development.
3. Customized Development Services: Tailored immunobiology services including biomaterial design and optimization, biomarker discovery screening, and immunoassay development and optimization for specific client requirements.
4. Recombinant Antibody Design Services: Biosimilar antibody cloning and development services starting from protein antibodies for therapeutic monoclonal antibody research.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Infynity Biomarkers develops, manufactures, and commercializes multiplex immunoassay research-use-only (RUO) kits and critical raw materials (antigens, antibodies) for the in vitro diagnostics industry. The company also provides recombinant antibody design and customized development services to support disease detection, therapeutic monitoring, and serological profiling for IVD companies and academic researchers.

Product overview

Infynity Biomarkers is an R&D biotechnology company specializing in immunology and infectiology, founded in 2009 and headquartered in Lyon, France. The company offers a portfolio of multiplex immunoassay kits (RUO), critical raw materials for IVD assays, recombinant antibody design services, and customized development services. The core technology is a 96-well microplate-based Multiplex Technology platform that can test up to 50 different antigens per well, supporting simultaneous detection of multiple biomarkers. Product offerings include Multi-SARS-CoV-2 Kit, Multi-Cruzi Kit, and Multi-HTLV Kit as immunoassay products; Critical Raw Materials (antigens and antibodies for HCV, HIV, HTLV, Chagas, Onchocerciasis, and Syphilis); Recombinant Antibody Design services for biosimilar development; and Customized Development Services covering biomaterial design, biomarker discovery, and immunoassay optimization. The MAGESTICS point-of-care platform is being developed in partnership with MAGIA Diagnostics and Grenoble Alpes Hospital. Target markets include in vitro diagnostics (infectiology, auto-immunity, allergy, oncology, neurodegenerative disease, immunotherapy monitoring), chemical diagnostics, and therapeutic companion diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• MAGESTICS: An Innovative Point-Of-Care diagnostics platform developed in collaboration with MAGIA Diagnostics and Grenoble Alpes Hospital (CHUGA), supported by BPI France and Rhône Alpes Region under a regional i-DEMO program.

Products and services

• Multiplex Immunoassay Kits (RUO) Research-use-only multiplex immunoassay kits built on the MAGESTICS platform that enable simultaneous profiling of multiple biomarkers in a single well for disease detection, therapeutic monitoring, and serological studies. Intended for IVD manufacturers and academic researchers.
• Critical Raw Materials (Antigens and Antibodies) Recombinant antigens and antibodies supplied as critical raw materials to IVD manufacturers for incorporation into diagnostic tests and assay development.
• Recombinant Antibody Design Service Custom recombinant antibody design and production service supporting clients who need tailored antibodies for specific diagnostic or research applications.
• Customized Development Services Tailored assay and product development services that adapt Infynity Biomarkers' multiplex and recombinant capabilities to client-specific diagnostic and research needs.
• MAGESTICS Platform Proprietary multiplex immunoassay platform underpinning the company's RUO kits, enabling high-content serological profiling within a single well.

Quantifiable outcome

• Up to 50 different antigens can be tested simultaneously in one well
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and major.

• MAGIA DiagnosticscoreStrategic or Co-development PartnerCollaborative partnership under the MAGESTICS project to develop an innovative point-of-care diagnostics platform. Project is supported by BPI France and Rhône Alpes Region under the regional i-DEMO program. INFYNITY BIOMARKERS, MAGIA Diagnostics and Grenoble Alpes Hospital (CHUGA) are the three partners in this initiative.
• Grenoble Alpes Hospital (CHUGA)coreStrategic or Co-development PartnerClinical partner in the MAGESTICS point-of-care diagnostics project. The hospital provides clinical expertise and testing facilities for the collaborative development initiative supported by BPI France and Rhône Alpes Region.
• Quotient LimitedcoreTechnology or IntegrationPartnership announced to expand the MosaiQ Infectious Disease Menu using Infynity Biomarkers' multiplex technology platform. This collaboration integrates Infynity's assays into Quotient's MosaiQ system for automated blood screening.
• DNDi (Drugs for Neglected Diseases initiative)majorStrategic or Co-development PartnerStrategic network partner for developing diagnostics for neglected tropical diseases, particularly Chagas disease. Infynity's research on Chagas disease has been featured in DNDi Chagas Platform Newsletters. The partnership involves collaboration on clinical studies and diagnostic development for neglected diseases.
• FINDmajorStrategic or Co-development PartnerStrategic network partner alongside DNDi. FIND (Foundation for Innovative New Diagnostics) is a global health organization focused on developing and delivering diagnostic solutions for poverty-related diseases.

Scale indicators5 records

Expansion highlights6 records

Direct peers

• InBios International: InBios develops and commercializes ELISA and rapid diagnostic tests for infectious diseases such as Chagas, dengue, and SARS-CoV-2, directly comparable to Infynity's infectious disease immunoassay kit portfolio.
• CTK Biotech: CTK Biotech manufactures rapid and ELISA diagnostic kits for infectious diseases including HIV, HTLV, and tropical diseases, overlapping with Infynity's infectious disease kit and raw materials portfolio.
• Meso Scale Diagnostics: Meso Scale Diagnostics offers multiplex immunoassay platforms (e.g., U-PLEX, V-PLEX) using 96-well plates to detect multiple analytes simultaneously, directly comparable to Infynity's multiplex platform for infectious disease and biomarker research.
• Luminex (DiaSorin): Now part of DiaSorin, Luminex pioneered bead-based multiplex assay technology (xMAP) used widely in infectious disease serology and biomarker research, competing directly with Infynity's multiplex immunoassay kits.

Broad incumbents

• GenScript: GenScript provides recombinant antibodies, antigens, and custom protein services for IVD and research customers, comparable to Infynity's critical raw materials and recombinant antibody design offerings.
• Quotient Limited: Quotient is both a partner and a comparable in the IVD blood screening space; its MosaiQ platform integrates Infynity's multiplex assays, placing it as a broader incumbent in serology-based infectious disease diagnostics.
• Bio-Techne: Bio-Techne provides a wide range of immunoassay reagents, antibodies, and assay kits, including multiplex platforms, overlapping with Infynity's portfolio of critical raw materials and custom assay services.
• Bio-Rad Laboratories: Bio-Rad is a major diagnostics and life science tools company with multiplex immunoassay offerings (e.g., Bio-Plex) and a broad infectious disease serology portfolio, making it a comparable larger incumbent in the same technology space.

Emerging players

• Chembio Diagnostics: Chembio develops point-of-care and ELISA-based infectious disease diagnostics, with overlap to Infynity's infectious disease menu and emerging POC direction through MAGESTICS.
• Omega Diagnostics: Omega Diagnostics develops IVD tests including multiplex platforms for infectious disease and food intolerance, comparable to Infynity's multiplex technology and infectious disease focus, though at a different scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/infynity-biomarkers

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Infynity Biomarkers